|LETTER TO EDITOR
|Year : 2022 | Volume
| Issue : 4 | Page : 1028
Serum BDNF in COVID-19 Patients: A Summative Analysis
Beuy Joob1, Viroj Wiwanitkit2
1 Private Academic Practice, Bangkok, Thailand
2 Department of Community Medicine, Dr. DY Patil University, Pune, Maharashtra, India
|Date of Submission||21-Mar-2021|
|Date of Decision||10-Dec-2021|
|Date of Acceptance||16-Dec-2021|
|Date of Web Publication||10-Feb-2023|
Dr. Beuy Joob
Private Academic Practice, Bangkok, Thailand, 13 Academic Center, Bangkok 112
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Joob B, Wiwanitkit V. Serum BDNF in COVID-19 Patients: A Summative Analysis. J Datta Meghe Inst Med Sci Univ 2022;17:1028
The COVID-19 is a new coronavirus infection. This infection causes pandemic and results in a worldwide public health problem. The infection manifests as an acute respiratory illness. However, it can also manifest atypical clinical presentation. The neuropsychiatric problem due to COVID-19 is also possible. The pathophysiological process relating to the angiotensin-converting enzyme 2\Mas\BDNF signaling pathway is mentioned. Alteration of serum DNF in COVID-19 patients is an interesting issue in laboratory medicine. There are few reports on serum BDNF determination in COVID-19 patients.,
Here, the authors perform a summative analysis for reappraisal on those available data on serum BDNF in COVID-19 patients. From 10 COVID-19 patients (five males and five females; age 7–90 years with average 52.5 ± 18.6 years), the average serum BDNF level is 5265.69 ± 2089.50 pg/mL. Comparing this level to the level in the normal population (range = 32690 ± 8330 pg/mL), the value in COVID-19 is lower. This can confirm the hypothesis that there might be downregulation and decreased expression of BDNF in COVID-19. Further studies on the BDNF level in COVID-19 in a larger sample size and the assessment of clinical association are recommended.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Tin SS, Wiwanitkit V. Uncommon atypical presentations of COVID-19: Important and should not be under recognized! J Health Sci Med Res 2020;38:153-8.
Motaghinejad M, Gholami M. Possible neurological and mental outcomes of COVID-19 infection: A hypothetical role of ACE-2\Mas\BDNF signaling pathway. Int J Prev Med 2020;11:84. [Full text]
Azoulay D, Shehadeh M, Chepa S, Shaoul E, Baroum M, Horowitz NA, et al.
Recovery from SARS-CoV-2 infection is associated with serum BDNF restoration. J Infect 2020;81:e79-81.
De Paulis M, Oliveira DB, Vieira RP, Pinto IC, Machado RR, Cavalcanti MP, et al.
Multisystem inflammatory syndrome associated with COVID-19 with neurologic manifestations in a child: A brief report. Pediatr Infect Dis J 2020;39:e321-4.